Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives

A crystal form and drug technology, which can be used in drug combinations, medical preparations containing active ingredients, allergic diseases, etc., and can solve the problems of poor drugability, poor water solubility, and low oral bioavailability.

Active Publication Date: 2022-07-26
SUNSHINE LAKE PHARM CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The inventor found that the compound has poor water solubility, low oral bioavailability, poor stability, and poor druggability when studying the compound, so it is necessary to find a solid form with better druggability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives
  • Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives
  • Crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0128] Embodiment 1 Crystal form I of the present invention

[0129] 1. Preparation of Form I

[0130] The compound represented by formula (I) (307 g) was prepared with reference to the method of Example 3 in International Application WO 2017088759 A1, which was dissolved in DMF (614 mL), heated to 80° C. and stirred for 0.5 h to dissolve, and then slowly cooled to room temperature , crystallization, suction filtration, the filter residue was washed with water (50 mL × 2), and air-dried at 70°C to obtain an off-white solid powder.

[0131] 2. Identification of Form I

[0132] (1) Identification by Empyrean X-ray powder diffraction (XRPD) analysis: using Cu-Kα radiation, with the following characteristic peaks represented by the angle 2θ: 7.44°, 7.78°, 8.24°, 12.69°, 12.95°, 14.08°, 14.75 °,15.03°,17.75°,19.71°,20.12°,20.81°,21.30°,21.89°,22.18°,23.27°,25.49°,25.85°,26.08°,26.60°,27.21°,27.44°,27.70°, 28.53° with an error tolerance of ±0.2°.

[0133] (2) Identification ...

Embodiment 2

[0134] Example 2 Amorphous of the present invention

[0135] 1. Amorphous Preparation

[0136] The crystalline form I (500 mg) of the compound represented by the formula (I) was added to DCM (5.0 mL), dissolved at room temperature, followed by rotary evaporation under reduced pressure to precipitate a solid, which was dried to obtain an off-white solid powder.

[0137] 2. Identification of Amorphous

[0138] Identified by Empyrean X-ray Powder Diffraction (XRPD) analysis: using Cu-Kα radiation, with substantially as image 3 An X-ray powder diffraction (XRPD) pattern is shown.

Embodiment 3

[0139] Example 3 Crystal form II of the present invention

[0140] 1. Preparation of Form II

[0141] The crystal form I (200 mg) of the compound represented by the formula (I) was added to ethyl acetate (2.0 mL), heated to 75° C. under stirring for 24 h, and the reaction was stopped, suction filtration, and drying to obtain an off-white solid powder, the target crystal form.

[0142] 2. Identification of Form II

[0143] (1) Identification by Empyrean X-ray Powder Diffraction (XRPD) analysis: using Cu-Kα radiation, with the following characteristic peaks represented by angle 2θ: 10.43°, 12.31°, 13.08°, 14.49°, 15.18°, 15.92°, 16.00 °,16.61°,16.90°,17.90°,18.42°,20.52°,21.04°,21.45°,23.59°,24.00°,24.26°,24.75°,25.07°,26.26°,26.53°,26.83°,28.02°, 28.31°, 29.31°, 30.03°, 30.42°, 31.20°, 31.56°, 32.25°, 32.80°, 33.63°, 34.24°, 35.54°, 36.41°, 36.96°, 38.33°, 38.78°, with ±0.2° Error tolerance.

[0144] (2) Identification by TA Q2000 Differential Scanning Calorimetry (DSC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to crystal forms of octahydropyrrolo[3,4-c]pyrrole derivatives. The present invention also relates to a pharmaceutical composition comprising the crystalline form, and the use of the crystalline form or the pharmaceutical composition in the manufacture of a medicament for preventing, treating or alleviating orexin receptor-related diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a crystal form of octahydropyrrolo[3,4-c]pyrrole derivatives, in particular to (5-(5-chlorobenzo[d]oxazol-2-yl)hexahydropyrrole) The crystalline form and The use thereof further relates to a pharmaceutical composition comprising the crystalline form. Background technique [0002] Orexin, also known as hypocretin, orexin, which includes orexin A and orexin B (or hypocretin-1 and hypocretin-2), is a hormone secreted by the hypothalamus. Its main physiological functions are: 1. Regulating feeding, orexin can activate neurons that regulate feeding, significantly promote feeding, and has a dose-dependent response; 2. Participate in the regulation of energy metabolism, orexin can significantly increase metabolism 3. Participate in the regulation of sleep-awakening, orexin can inhibit rapid eye movement sleep, prolong the awakening time, and block the effect of orexin can promote sleep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D487/04A61K31/423A61P25/20A61P25/24A61P25/22A61P25/28A61P25/18A61P25/30A61P25/14A61P25/06A61P25/08A61P25/00A61P25/04A61P25/16A61P29/00A61P9/00A61P3/10A61P3/00A61P5/00A61P9/12A61P37/02
CPCC07D487/04A61P25/20A61P25/24A61P25/22A61P25/28A61P25/18A61P25/30A61P25/14A61P25/06A61P25/08A61P25/00A61P25/04A61P25/16A61P29/00A61P9/00A61P3/10A61P3/00A61P5/00A61P9/12A61P37/02C07B2200/13
Inventor 金传飞许腾飞张英俊
Owner SUNSHINE LAKE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com